ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY

QR Code

ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY

We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan,...

Full description

Saved in:

Bibliographic Details
Main Authors:	H. Yokoyama, D. B. Averill, K. B. Brosnihan, R. D. Smith, E. L. Schiffrin, C. M. Ferrario
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2011-08-01
Series:	Российский кардиологический журнал
Subjects:	atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/1131
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors
by: R. D. Smith, et al.
Published: (2010-12-01)

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study
by: Kl. O. Stumpe, et al.
Published: (1970-01-01)

Psychosomatic status and myocardial hypertrophy remodelling specificity
by: G. A. Usenko, et al.
Published: (2018-12-01)

SIRT5 prevents mitochondrial dysfunction and cardiac hypertrophy induced by RIP140
by: Liying Liang, et al.
Published: (2025-04-01)

Role of cardio-ankle vascular index as a predictor of left ventricular hypertrophy in the evaluation of pediatric hypertension
by: Evan Harvey, et al.
Published: (2024-04-01)

Surrogate atherosclerosis markers in patients with stage I-II arterial hypertension
by: E. A. Grigoricheva, et al.
Published: (2009-02-01)

Pharmacological potential in regression of left ventricular hypertrophy in hypertensive patients
by: G. G. Taradin, et al.
Published: (2025-03-01)

USP10 protects against pressure overload-induced mitochondrial morphofunctional defects and pathological cardiac hypertrophy through stabilizing cytoplasmic Mfn2
by: Runjing Li, et al.
Published: (2025-09-01)

Cardiomyopathies with left ventricular hypertrophy phenotype: prevalence of cardiac amyloidosis and clinical characteristics of patients
by: A.S. Kozliuk
Published: (2025-06-01)

Cardiovascular remodeling and calcium-regulating function of parathyroid glands in arterial hypertension
by: B. G. Iskenderov, et al.
Published: (2007-04-01)

The effectiveness of phosphocreatine cardioprotection during vascular surgery in high cardiac risk patients
by: I. A. Kozlov, et al.
Published: (2024-06-01)

The influence of renal anemia on cardiac remodelling in chronic glomerulonephritis
by: I. T. Murkamilov, et al.
Published: (2016-10-01)

Circumferentially Aligned Electrospun Vascular Grafts Improves Its Vascular Regeneration and Remodeling in vivo
by: Xiong M, et al.
Published: (2025-06-01)

miR-424/322 attenuates cardiac remodeling by modulating the nuclear factor-activated T-cell 3/furin pathway
by: Hsiao-Ya Tsai, et al.
Published: (2025-08-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

Transplantation of cardiac allografts with left ventricular hypertrophy 1.5 cm and more
by: V. N. Poptsov, et al.
Published: (2019-05-01)

THE WAYS OF SYMPATHETIC SYSTEM OVERACTIVITY BLOCKING: RILMENIDINE VERSUS ATENOLOL
by: Y. R. Kasherininov, et al.
Published: (2016-01-01)

vASCULAR AND CARDIAC REMODELLING AND COMbINATION THERAPY OF ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONIC ObSTRUCTIvE PULMONARY DISEASE
by: L. A. Shpagina, et al.
Published: (2014-01-01)

Severe myocardial hypertrophy and fibrosis in a patient with acromegaly: is the prevention of sudden cardiac death needed?
by: A. A. Almaskhanova, et al.
Published: (2024-07-01)

Pim3 up-regulation by YY1 contributes to diabetes-induced cardiac hypertrophy and heart failure
by: Xiao Jin, et al.
Published: (2025-02-01)

Comparison of the association of brachial arterial pressure and parameters of central aortic pressure with left ventricular hypertrophy in the general population of Novosibirsk
by: E. E. Tsvetkova, et al.
Published: (2019-02-01)

The effectiveness of succinate cardioprotection during vascular surgery in high cardiac risk patients
by: I. A. Kozlov, et al.
Published: (2024-02-01)

Effects of chronic airway obstruction and atrial fibrillation on the cardiac structure and function in patients with heart failure
by: A. I. Chesnikova, et al.
Published: (2020-03-01)

COMPARISON OF FOSINOPRIL AND ATENOLOL EFFECT ON HEART 0.1 HZ-RHYTHMS SYNCHRONIZATION AND BLOOD MICROCIRCULATION IN PATIENTS WITH ARTERIAL HYPERTENSION
by: A. R. Kiselev, et al.
Published: (2016-01-01)

IVABRADIN AND ATENOLOL EFFECTIVENESS COMPARISON IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
by: P. Kh. Dzhanashiya, et al.
Published: (2010-02-01)

Study the effect of Atenolol drug in kidneys of Adult Swiss white mice
by: Nada Aziz Khalid, et al.
Published: (2023-01-01)

Distinct morphometric features of cardiomyocytes isolated from mouse hypertrophy models: An ImageJ analysis combined with machine learning algorithms
by: Hoang Duc Minh Pham, et al.
Published: (2025-06-01)

MiR-133b-3p attenuates angiotensin II-induced cardiac hypertrophy through the inhibition of apoptosis by targeting CDIP1
by: Gu Jiwei, et al.
Published: (2025-02-01)

Cardiac and vascular changes in the patho- and morphogenesis of alcohol use disorder
by: V. S. Paukov, et al.
Published: (2020-11-01)

PREDICTION ROLE OF THE LEFT VENTRICLE REMODELLING IN ARTERIAL HYPERTENSION PATIENTS
by: S. V. Ivanova, et al.
Published: (2016-12-01)

PREDICTION ROLE OF THE LEFT VENTRICLE REMODELLING IN ARTERIAL HYPERTENSION PATIENTS
by: S. V. Ivanova, et al.
Published: (2016-12-01)

THE EFFECT OF NEBIVOLOL ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH MILD HYPERTENSION
by: I. L. Tepoyan, et al.
Published: (2015-09-01)

HEART REMODELING IN OVERWEIGHT AND OBESITY WITH CARDIAC COMORBIDITIES
by: I. V. Logacheva, et al.
Published: (2017-05-01)

LEFT VENTRICULAR HYPERTROPHY IN PATIENTS ON CHRONIC HAEMODIALYSIS
by: A. G. Strokov, et al.
Published: (2010-06-01)

The effectiveness of dexmedetomidine cardioprotection during vascular surgery in high cardiac risk patients
by: I. A. Kozlov, et al.
Published: (2024-04-01)

THE ROLE OF VASCULAR REMODELING IN THE FORMATION OF STRUCTURAL PHENOTYPES OF OSTEOARTHRITIS
by: M. A. KABALYK, et al.
Published: (2018-07-01)

PERIOPERATIVE PERIOD FOLLOWING HEART TRANSPLANTATION WITH SEVERE LEFT VENTRICULAR HYPERTROPHY
by: V. N. Poptsov, et al.
Published: (2012-05-01)

The effectiveness of cytocardioprotection of patients with the moderately expressed post infarct dysfunction of left heart ventricle: the results of the randomization research of trimetazidine and athenolole
by: V. V. Kalyuzhin, et al.
Published: (2002-03-01)

Morphometric changes of the left ventricle and characteristics of peripheral hemodynamics in patients with drug resistant hypertension
by: R. R. Kushkhova, et al.
Published: (2016-09-01)

Spirapril effects on heart remodeling in patients with mild to moderate arterial hypertension
by: M. M. Beraya, et al.
Published: (2007-02-01)